What is the success rate of imbruvica for mantle cell lymphoma?

What is the real-world success rate of Imbruvica for mantle cell lymphoma?

Real-world studies report overall response rates of 66% and progression-free survival around 15 months, compared with clinical trial results of 66-68% overall response rates and 14-21 months progression-free survival. Real-world data often show etwas tiefer response rates than trials, but still significant clinical benefit.

Why do clinical trials and real-world data differ?

Trial patients are usually younger, fit enough to meet inclusion criteria, and have fewer comorbidities than patients treated in routine practice. Com comorbidities often affect a patient's ability to stop or adjust dose due to side effects.